 Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq: EIGR, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus HDV and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV. 